Marisa Wexler, MS,  senior science writer—

A new analysis suggests that the doses of rodatristat ethyl — an investigational therapy for pulmonary arterial hypertension (PAH) — now being evaluated in the Phase 2b ELEVATE 2 clinical trial are likely to reduce levels of the hormone serotonin to an extent that has been demonstrated to…

An updated application has been filed with the U.S. Food and Drug Administration (FDA), again asking that LIQ861 be approved as an inhalation treatment of pulmonary arterial hypertension (PAH), its developer Liquidia announced. The company first made this request in an application to the FDA submitted in April 2020. But the…

By screening thousands of potential candidates, researchers have identified a compound, called AG1296, that may be useful for the treatment of pulmonary arterial hypertension (PAH). Their findings were published in the journal Science Translational Medicine, in a study, “iPSC–endothelial cell phenotypic drug screening and in silico…

Activation of a protein called aryl hydrocarbon receptor (AHR) is essential for the development of pulmonary arterial hypertension (PAH), a study found. The findings imply that targeting AHR could be a useful strategy to treat PAH, according to researchers. The results were published in the journal PNAS, in…

Treatment with a fungus called Ophiocordyceps sinensis eased disease signs and improved survival in a rat model of pulmonary arterial hypertension (PAH), suggesting a potential to treat patients. The findings were in the study “Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on…

Treatment with the investigational medication levosimendan was found to improve exercise tolerance, and some parameters related to heart function, in a small clinical trial of people with pulmonary hypertension and heart failure with preserved ejection fraction — a condition known as PH-HFpEF. In fact, 84% of patients in the…

Experts will discuss how the COVID-19 pandemic has affected people living with pulmonary hypertension and other rare respiratory diseases during a live panel discussion this week. The event, taking place on Tuesday, March 23, at 7 p.m. CET (2 p.m. EST), is being put on by the European…

Acute pulmonary hypertension (aPH) is frequent and linked with a higher risk of mortality in people who are severely ill with COVID-19, according to a Swedish study. The study, “Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care,” was published in the journal…

People with pulmonary hypertension are less likely to be referred to exercise therapy if they are of lower socioeconomic status or perceive more barriers to accessing such therapy, a study shows. These findings highlight the need for increased education about the benefits of exercise for people with pulmonary hypertension,…

PhaseBio Pharmaceuticals‘s investigational therapy pemziviptadil (PB1046) showed a good safety profile and clinically meaningful effects on physical function in a small clinical trial of three people with pulmonary arterial hypertension (PAH). The findings support further evaluation of pemziviptadil as…

The European Commission has granted orphan drug designation to sotatercept for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications with the potential to substantially improve care for rare diseases — defined as those that affect fewer than five individuals per 10,000…

Enrollment is resuming for the VIP clinical trial, which is evaluating PhaseBio Pharmaceuticals‘ investigational therapy pemziviptadil (PB1046) in people with pulmonary arterial hypertension (PAH). The trial, which is recruiting adult patients at sites across the U.S., underwent a brief pause in enrollment owing to effects of the…